Capricor says Deramiocel BLA talks continue with FDA
Capricor Therapeutics says it remains engaged with the FDA on Deramiocel’s BLA after a BIMO inspection produced a Form 483 with one observation that it has addressed.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.